NCT01541449

Brief Summary

The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2012

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 2, 2012

Completed
28 days until next milestone

First Posted

Study publicly available on registry

March 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

March 1, 2012

Status Verified

January 1, 2012

First QC Date

February 2, 2012

Last Update Submit

February 29, 2012

Conditions

Age Related Macular Degeneration

Keywords

AMDPLAQUENILCNV

Study Arms (2)

RA patients treated with plaquenil

Patients who do not use plaquenil

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Ziv Medical center retina clinic population

You may qualify if:

  • all people who suffer from rheumatoid arthritis (RA) and use plaquenil

You may not qualify if:

  • patients who did not complete follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ziv Medical Center

Safed, 13100, Israel

RECRUITING

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Joseph pikkel, M.D

    Ziv Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Joseph Pikkel, M.D

CONTACT

0508434206pikel.y@ziv.health.gov.il

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2012

First Posted

March 1, 2012

Study Start

January 1, 2012

Study Completion

April 1, 2012

Last Updated

March 1, 2012

Record last verified: 2012-01

Locations

IL(1)